The 2nd NASH Summit Europe fills the gap as the only industry-led forum dedicated to harnessing the NASH biopharmaceutical understanding and focusing on the most pressing drug development challenges with a tighter lens, including:
 

• •  The potential for stand-alone versus combination therapeutics
• •  The genetic drivers influencing disease heterogeneity
• •  The future payer and reimbursement landscape

Built from research with 20 NASH stakeholders including the FDA, EMA and Gilead; the 2nd NASH Summit Europe brings together the leading experts in the only forum dedicated exclusively to collaborative discussion and networking for NASH drug developers.